<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Pediatr Blood Cancer</journal-id>
      <journal-id journal-id-type="iso-abbrev">Pediatr Blood Cancer</journal-id>
      <journal-id journal-id-type="publisher-id">pbc</journal-id>
      <journal-title-group>
        <journal-title>Pediatric Blood &amp; Cancer</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1545-5009</issn>
      <issn pub-type="epub">1545-5017</issn>
      <publisher>
        <publisher-name>Blackwell Publishing Ltd</publisher-name>
        <publisher-loc>Oxford, UK</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">25156525</article-id>
      <article-id pub-id-type="pmc">4344820</article-id>
      <article-id pub-id-type="doi">10.1002/pbc.25173</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Letters to the Editor</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Synchronous and Metachronous Thyroid Cancer in Relation to Langerhans Cell
Histiocytosis; Involvement of <italic>V600E BRAF-</italic>Mutation?</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Moschovi</surname>
            <given-names>Maria</given-names>
          </name>
          <degrees>MD</degrees>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Adamaki</surname>
            <given-names>Maria</given-names>
          </name>
          <degrees>PHD</degrees>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Vlahopoulos</surname>
            <given-names>Spiros</given-names>
          </name>
          <degrees>PHD</degrees>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Rodriguez-Galindo</surname>
            <given-names>Carlos</given-names>
          </name>
          <degrees>MD</degrees>
        </contrib>
        <aff>Maria Moschovi, MD, Maria Adamaki, PHD, Spiros Vlahopoulos, PHD, <institution>Pediatric Hematology/Oncology Unit, First Department of Pediatrics,
University of Athens, &#x201C;Aghia Sofia&#x201D; Children's Hospital</institution><addr-line>Athens, Greece</addr-line></aff>
        <aff>Carlos Rodriguez-Galindo, MD, <institution>Department of Pediatric Hematology and Oncology, Dana-Farber/Boston
Children's Cancer and Blood Disorders Center</institution><addr-line>Boston, Massachusetts, United States of America, USA</addr-line></aff>
      </contrib-group>
      <author-notes>
        <corresp id="cor1">*Correspondence to: Maria Moschovi, Pediatric Hematology/Oncology Unit,
First Department of Pediatrics, University of Athens &#x201C;Aghia Sofia&#x201D; Children's
Hospital Thivon &amp; Levadeias Street 11527 Goudi Athens, Greece. E-mail:
<email>mmoschov@med.uoa.gr</email></corresp>
        <fn>
          <p>[The copyright line was updated on 20 January 2015 after original online
publication.]</p>
        </fn>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>1</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>22</day>
        <month>8</month>
        <year>2014</year>
      </pub-date>
      <volume>62</volume>
      <issue>1</issue>
      <fpage>173</fpage>
      <lpage>174</lpage>
      <history>
        <date date-type="received">
          <day>27</day>
          <month>5</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>16</day>
          <month>6</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; 2014 The Authors. <italic>Pediatric Blood &amp; Cancer</italic>,
published by Wiley Periodicals, Inc.</copyright-statement>
        <copyright-year>2014</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
          <license-p>This is an open access article under the terms of the Creative Commons Attribution-NonCommercial
License, which permits use, distribution and reproduction in any medium, provided the original work
is properly cited and is not used for commercial purposes.</license-p>
        </license>
      </permissions>
    </article-meta>
  </front>
  <body>
    <p>Langerhans cell histiocytosis (LCH) (cells identified in 1868, disease named in 1985), has a wide
range of clinical presentations, including the rare event of infiltration of the thyroid gland.
However, an association seems to exist between LCH and papillary thyroid carcinoma (PTC), as eight
cases of LCH co-existing with PTC have been described in the english literature [<xref rid="b1" ref-type="bibr">1</xref>]. We extend this association with a metachronous case of
PTC, occurring 4 years from the diagnosis of LCH, while the LCH was in remission (Table <xref ref-type="table" rid="tblI">I</xref>).</p>
    <table-wrap id="tblI" position="float">
      <label>TABLE I</label>
      <caption>
        <p>Time of Presentation of Papillary Thyroid Carcinoma (PTC) in Relation to the Diagnosis of LCH</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th rowspan="1" colspan="1"/>
            <th align="left" rowspan="1" colspan="1">Case reference</th>
            <th align="left" rowspan="1" colspan="1">Age/sex</th>
            <th align="left" rowspan="1" colspan="1">Case description</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="left" rowspan="1" colspan="1">Synchronous</td>
            <td align="left" rowspan="1" colspan="1">Vergez <italic>et al</italic> (2010) [<xref rid="b1" ref-type="bibr">1</xref>]</td>
            <td align="left" rowspan="1" colspan="1">37yr/F</td>
            <td align="left" rowspan="1" colspan="1">Simultaneous presentation of PTC and LCH</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td align="left" rowspan="1" colspan="1">31yr/F</td>
            <td align="left" rowspan="1" colspan="1">Thyromegaly secondary to simultaneous PTC and LCH</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td align="left" rowspan="1" colspan="1">38yr/F</td>
            <td align="left" rowspan="1" colspan="1">Simultaneous presentation ofPTC and LCH</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td align="left" rowspan="1" colspan="1">43yr/M</td>
            <td align="left" rowspan="1" colspan="1">LCH in association with a small focus of papillary carcinoma</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td align="left" rowspan="1" colspan="1">42yr/F</td>
            <td align="left" rowspan="1" colspan="1">LCH confined to the thyroid and associated with lymphocytic thyroiditis and a
papillary microcarcinoma</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td align="left" rowspan="1" colspan="1">3yr/M</td>
            <td align="left" rowspan="1" colspan="1">Case presented with goiter; simultaneous presentation of LCH with PTC</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td align="left" rowspan="1" colspan="1">24yr/M</td>
            <td align="left" rowspan="1" colspan="1">Invasive papillary cancer of the thyroid simultaneously with LCH</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1"/>
            <td rowspan="1" colspan="1"/>
            <td align="left" rowspan="1" colspan="1">29yr/M</td>
            <td align="left" rowspan="1" colspan="1">Bone, lung, skin, thyroid, and hypothalamo-pituitary LCH lesions with concomitant
presentation of PTC</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">Metachronous</td>
            <td align="left" rowspan="1" colspan="1">Moschovi <italic>et al</italic> (present letter)</td>
            <td align="left" rowspan="1" colspan="1">9yr/M</td>
            <td align="left" rowspan="1" colspan="1">Thyroid cancer appearing 4 years following diagnosis of LCH, while the patient was
in complete remission</td>
          </tr>
        </tbody>
      </table>
    </table-wrap>
    <p>In our case PTC was metachronous and not therapy related. This is verified by the fact that the
patient did not receive etoposide or high doses of methotrexate, or local radiotherapy [<xref rid="b2" ref-type="bibr">2</xref>,<xref rid="b3" ref-type="bibr">3</xref>]. The radiation
exposure was minimal; only two X-rays were performed at diagnosis, while imaging of the head was
performed with MRI and no CT-scans. Therefore, a causative relationship is highly unlikely. More
specifically, a 9-year-old boy, with low risk [RO-]LCH, <italic>V600E BRAF</italic>
mutation positive, received vinblastine/prednisolone according to the LCH III protocol, and achieved
remission. Four years following diagnosis of LCH, in the routine follow-up, an 8 mm lesion was
revealed in the thyroid gland by ultrasound. Total resection of the thyroid gland revealed a
<italic>V600E BRAF</italic> mutation-negative papillary carcinoma, while it was negative for LCH
[SD100&#x2212;, CD1a&#x2212;, Langerin&#x2212;].</p>
    <p>No information exists on the <italic>V600E BRAF</italic> mutation status from the LCH cases
co-existing with PTC [<xref rid="b1" ref-type="bibr">1</xref>]. In our case, the LCH
sample was positive for the <italic>V600EBRAF</italic> mutation, while the PTC was negative for the
mutation. It is possible that LCH and PTC share a common determinant, despite the different
<italic>BRAF</italic> mutation status, as approximately half of the reported cases of LCH are
negative for the mutation and only around half of the reported PTCs are positive for the mutation
[<xref rid="b4" ref-type="bibr">4</xref>]. The role of the <italic>V600E BRAF</italic>
mutation is currently unknown. One could speculate that, since the LCH has been shown to increase
the expression of T-helper type 2 cytokines [<xref rid="b5" ref-type="bibr">5</xref>],
the presence of the <italic>V600E BRAF</italic> mutation could exacerbate this defect in LCH
cytokine regulation. Thus, the particular oncogene might be eliciting an inflammatory
pro-tumorigenic microenvironment, possibly linking the LCH-induced deregulated immunologic cascade
to neoplastic transformation. It would be of great interest to have more information on the
<italic>BRAF</italic> mutation status from cases of LCH co-existing with PTC, as it would help to
elucidate the role of <italic>V600E BRAF</italic> mutation in PTC development.</p>
    <p>In summary, the thyroid gland is a potential target organ for LCH, both through direct
involvement of the disease and through its association with the development of thyroid carcinoma.
Thus, routine evaluation of the thyroid gland at diagnosis and during follow-up should be
considered. Further research is needed to understand the association of LCH with PTC, as well as the
molecular and immunological basis for this tropism to the thyroid gland.</p>
  </body>
  <back>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="b1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vergez</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Rouquette</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Ancey</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Langerhans cell histiocytosis of the thyroid is a rare entity, but an association
with a papillary thyroid carcinoma is often described</article-title>
          <source>Endocr Pathol</source>
          <year>2010</year>
          <volume>21</volume>
          <fpage>274</fpage>
          <lpage>276</lpage>
          <pub-id pub-id-type="pmid">20848238</pub-id>
        </element-citation>
      </ref>
      <ref id="b2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Haupt</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Fears</surname>
              <given-names>TR</given-names>
            </name>
            <name>
              <surname>Heise</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Risk of secondary leukemia after treatment with etoposide (VP-16) for
Langerhans' cell histiocytosis in Italian and Austrian-German populations</article-title>
          <source>Int J Cancer</source>
          <year>1997</year>
          <volume>71</volume>
          <fpage>9</fpage>
          <lpage>13</lpage>
          <pub-id pub-id-type="pmid">9096658</pub-id>
        </element-citation>
      </ref>
      <ref id="b3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Haupt</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Nanduri</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Calevo</surname>
              <given-names>MG</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Permanent consequences in Langerhans cell histiocytosis patients: a pilot study from
the Histiocyte Society-Late Effects Study Group</article-title>
          <source>Pediatr Blood Cancer</source>
          <year>2004</year>
          <volume>42</volume>
          <fpage>438</fpage>
          <lpage>444</lpage>
          <pub-id pub-id-type="pmid">15049016</pub-id>
        </element-citation>
      </ref>
      <ref id="b4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>De Biase</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Cesari</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Visani</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>High sensitivity BRAF mutation analysis: BRAF v600E is acquired early during tumor
development but is heterogeneously distributed in a subset of papillary thyroid
carcinomas</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2014</year>
          <fpage>jc20134389</fpage>
        </element-citation>
      </ref>
      <ref id="b5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tsuji</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Kogawa</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Imai</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Evans syndrome in a patient with Langerhans cell histiocytosis: possible pathogenesis
of autoimmunity in LCH</article-title>
          <source>Int J Hematol</source>
          <year>2008</year>
          <volume>87</volume>
          <fpage>75</fpage>
          <lpage>77</lpage>
          <pub-id pub-id-type="pmid">18224417</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
